DLA Piper represents Arsenal Capital Partners in acquisition of Certara from Vector Capital
DLA Piper has represented Arsenal Capital Partners, a New York private equity firm specialising in middle-market healthcare and industrial companies, in its purchase of Certara, a biopharmaceutical service provider that provides data analytics software, consulting and model-based drug development.
Certara’s technology-based products provide specialised solutions for the entire span of drug discovery and development. The purchase of Certara will assist Arsenal in the creation of products and methods for reducing the time and expense spent developing and marketing new drugs.
The DLA Piper team representing Arsenal Capital Partners was led by Daniel Eisner, partner in the corporate and finance practice in New York, and included Sidney Burke, Gregory Ruback and Bruce Wein in New York; William Bartow in Philadelphia; Rita Patel in Washington DC; and Alexandra Lauvaux, Frank Mugabi, Sarah Castle, Jacob Frumkin and Erin D’Angelo, all in New York.
Internationally, the team included Carlos Rodriguez, Joaquin Echanove and Luis Borrero in Madrid; Clare Gregory and David Beech in Sheffield; Denis-Emmanuel Philippe and Pierre-Yves Genot in Brussels; and Marie-Eve Delpech in Luxembourg.
News from DLA Piper
News from The Lawyer
Briefings from DLA Piper
Cour de Cassation quashes decision that disregarded ICC rule on time limits to arbitrator challenges — two takeaways
This milestone decision further limits the scope for French courts to annul arbitration awards and reinforces the efficiency of France-seated arbitral proceedings.
This decision is in line with a possible judicial trend towards enforceability of good faith obligations under English law.
Analysis from The Lawyer
Shearman & Sterling is making its presence felt in the City, squaring up to magic circle firms and looking to muscle in on key relationships. Private equity house Bridgepoint is one outfit that has had its head turned by the US firm.
A new breed of lawyer is smoothing the path for companies entering emerging or unstable jurisdictions